Table 1.

HIV phase I/II/III tested by the US Army.

Vaccine	Trial (# of participants)	Company
Gp120SF2(B)/MF59 (87)	Phase I (n = 52)	Chiron
Gp120SF2(B)/MF59 + gp120CM235/MF59 (88)	Phase II (n = 370)	Chiron
ALVAC-HIV (vCP1521) prime + oligomeric gp160 (92TH023/LAI-DID) or ALVAC-HIV (vCP1521) prime + bivalent gp120 (CM235/SF2) (93)	Phase I/II n = 130	Sanofi Pasteur and Novartis Vaccine and Diagnostics
ALVAC-HIV (vCP1521) prime + AIDSVAX B/E (92)	Phase I/II n = 122	Sanofi Pasteur and VaxGen
ALVAC-HIV (vCP1521) prime + AIDSVAX B/E (94)	Phase III n = 16,402	Sanofi Pasteur and VaxGen
MVA CMDR (CRF01_AE) (95)	Phase I n = 48	LVD/NIAID/WRAIR/MHRP
PENNVAX-G DNA + MVA-CMDR (96)	Phase I n = 88	Innovio Pharmaceutical + LVD/NIAID/WRAIR/MHRP